Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland.
Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland.
Neuromodulation. 2022 Aug;25(6):918-924. doi: 10.1111/ner.13362. Epub 2022 Jun 14.
The study aimed to present a family with myoclonus dystonia (M-D) syndrome due to a mutation in the epsilon sarcoglycan gene (SGCE). Three members of the family suffered from treatment-refractory severe myoclonic jerks of the neck, trunk, and upper extremities. The mild dystonic symptoms recognized as cervical dystonia or truncal dystonia affected all individuals. The efficacy of pharmacotherapy, including anticholinergic, dopaminergic, and serotoninergic drugs, has failed. One individual developed an alcohol dependency and suffered from alcoholic epilepsy.
The patients were referred for stereotactic surgery. All individuals underwent bilateral implantation of deep brain stimulation (DBS) leads into the posteroventrolateral segment of the globus pallidus internus (GPi). Surgeries were uneventful. The formal preoperative objective assessment included the Unified Myoclonus Rating Scale (UMRS) and the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). The postoperative UMRS and BFMDRS assessments were done only under continuous stimulation at 3, 6, and 12 months after the surgery and at the last available follow-up ranging from 6 to 15 months (mean, 10 months follow-up).
At the last follow-up visit, the rest and action parts of UMRS were improved by 93.3% and 88.2%, respectively, when compared to the baseline scores. The motor and disability scales of BFMDRS were improved by 77% and 43% at the last follow-up visit compared to the baseline BFMDRS scores. There were no hardware or stimulation-induced complications over the follow-up period. Positive social adjustment allowed two patients to regain jobs and one patient continued his education and hobbies.
Our experience gathered in three individuals in the family with a mutation in SGCE indicates that bilateral GPi DBS can be an effective and safe treatment for disabling pharmacological resistant, intractable M-D syndrome.
本研究旨在报道一个肌阵挛性张力障碍(M-D)综合征家系,其致病突变位于ε-肌聚糖(SGCE)基因。家系中有 3 名成员患有抗药性重度颈部、躯干和上肢肌阵挛性抽搐。所有个体均表现出轻度的、被识别为颈肌张力障碍或躯干肌张力障碍的扭转痉挛症状。抗胆碱能、多巴胺能和 5-羟色胺能药物等药物治疗均无效。其中 1 名个体发展为酒精依赖,并患有酒精性癫痫。
患者被转诊接受立体定向手术。所有个体均接受双侧深部脑刺激(DBS)电极植入苍白球内侧后腹段(GPi)。手术过程均顺利。正式的术前客观评估包括统一肌阵挛评定量表(UMRS)和 Burke-Fahn-Marsden 肌张力障碍评定量表(BFMDRS)。术后 UMRS 和 BFMDRS 评估仅在手术 3、6 和 12 个月后以及最后一次可获得的随访时(6 至 15 个月,平均 10 个月随访)进行,且在连续刺激下进行。
在最后一次随访时,与基线评分相比,UMRS 的休息和动作部分分别改善了 93.3%和 88.2%。与基线 BFMDRS 评分相比,BFMDRS 的运动和残疾评分在最后一次随访时分别改善了 77%和 43%。在随访期间,未出现硬件或刺激诱导的并发症。积极的社会调整使两名患者能够重新就业,一名患者继续其教育和爱好。
我们在一个具有 SGCE 基因突变的家系中对 3 名个体的经验表明,双侧 GPi DBS 是一种治疗致残性、抗药性难治性 M-D 综合征的有效且安全的方法。